161 related articles for article (PubMed ID: 30353885)
1. Optimizing concentrations of concomitant antiretrovirals by reducing etravirine doses: two case reports of complex drug-drug interactions.
Denault JS; Cabot JF; Langlois H; Marcotte S; Sheehan NL
Antivir Ther; 2019; 24(1):73-76. PubMed ID: 30353885
[TBL] [Abstract][Full Text] [Related]
2. Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation.
Cattaneo D; Baldelli S; Cozzi V; Fusi M; Atzori C; Micheli V; Filice C; Gervasoni C
Ther Drug Monit; 2020 Apr; 42(2):330-334. PubMed ID: 31743292
[TBL] [Abstract][Full Text] [Related]
3. From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.
Fang J; Jadhav PR
J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):357-68. PubMed ID: 22736302
[TBL] [Abstract][Full Text] [Related]
4. Effect of Carbamazepine on Darunavir Trough Concentrations: When the Dose Can Make the Difference-A Case Study.
Cattaneo D; Caloni B; Caronni S; Calvagna N; Bonini I; Giacomelli A; Gervasoni C
Ther Drug Monit; 2024 Jun; 46(3):277-280. PubMed ID: 38723113
[TBL] [Abstract][Full Text] [Related]
5. Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV.
Fulco PP; Leibrand Kaczmar CR; Gomes D; Smith T
J Clin Pharm Ther; 2020 Apr; 45(2):394-396. PubMed ID: 31765502
[TBL] [Abstract][Full Text] [Related]
6. Dolutegravir for the treatment of adult patients with HIV-1 infection.
Wu G; Abraham T; Saad N
Expert Rev Anti Infect Ther; 2014 May; 12(5):535-44. PubMed ID: 24694091
[TBL] [Abstract][Full Text] [Related]
7. Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).
Rusconi S; Adorni F; Tau P; Borghi V; Pecorari M; Maserati R; Francisci D; Monno L; Punzi G; Meraviglia P; Paolucci S; Di Biagio A; Bruzzone B; Mancon A; Micheli V; Zazzi M;
J Clin Virol; 2018 Aug; 105():112-117. PubMed ID: 29957545
[TBL] [Abstract][Full Text] [Related]
8. Update on raltegravir and the development of new integrase strand transfer inhibitors.
Shamroe CL; Bookstaver PB; Rokas KE; Weissman SB
South Med J; 2012 Jul; 105(7):370-8. PubMed ID: 22766666
[TBL] [Abstract][Full Text] [Related]
9. Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea.
Kwon OK; Kim SS; Rhee JE; Kee MK; Park M; Oh HR; Choi JY
Virol J; 2015 Apr; 12():53. PubMed ID: 25879840
[TBL] [Abstract][Full Text] [Related]
10. Etravirine: new drug. Multidrug-resistant HIV: another option.
Prescrire Int; 2009 Jun; 18(101):102-3. PubMed ID: 19637414
[TBL] [Abstract][Full Text] [Related]
11. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
Chouchana L; Beeker N; Treluyer JM
J Acquir Immune Defic Syndr; 2019 Aug; 81(4):481-486. PubMed ID: 31021990
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
Baldin G; Ciccullo A; Capetti A; Rusconi S; Sterrantino G; Cossu MV; Giacomelli A; Lagi F; Latini A; Bagella P; De Luca A; Di Giambenedetto S; Madeddu G
HIV Med; 2019 Feb; 20(2):164-168. PubMed ID: 30457197
[TBL] [Abstract][Full Text] [Related]
13. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Stellbrink HJ; Arribas JR; Stephens JL; Albrecht H; Sax PE; Maggiolo F; Creticos C; Martorell CT; Wei X; Acosta R; Collins SE; Brainard D; Martin H
Lancet HIV; 2019 Jun; 6(6):e364-e372. PubMed ID: 31068272
[TBL] [Abstract][Full Text] [Related]
14. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
[TBL] [Abstract][Full Text] [Related]
16. Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review.
Llibre JM; Álvarez H; Yzusqui M
AIDS Rev; 2018; 20(3):158-170. PubMed ID: 30264825
[TBL] [Abstract][Full Text] [Related]
17. Hepatoxicity of new antiretrovirals: a systematic review.
Surgers L; Lacombe K
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):126-33. PubMed ID: 23522569
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir with boosted darunavir as treatment simplification for treatment-experienced HIV patients with multiple mutations.
Paparizos V; Vasalou V; Kourkounti S
Int J STD AIDS; 2019 Oct; 30(12):1214-1215. PubMed ID: 31775586
[No Abstract] [Full Text] [Related]
19. Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.
Green B; Crauwels H; Kakuda TN; Vanveggel S; Brochot A
Clin Pharmacokinet; 2017 May; 56(5):525-536. PubMed ID: 27665573
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma.
Bollen PDJ; de Graaff-Teulen MJA; Schalkwijk S; van Erp NP; Burger DM
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():76-84. PubMed ID: 30572204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
